-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the 40 years since the report on Acquired Immune Deficiency Syndrome (AIDS, commonly known as AIDS) was first published , more than 32 million people have died from the virus that causes AIDS, the human immunodeficiency virus (HIV)
In the 40 years since the report on Acquired Immune Deficiency Syndrome (AIDS, commonly known as AIDS) was first published , more than 32 million people have died from the virus that causes AIDS, the human immunodeficiency virus (HIV)
Broadly neutralizing antibodies (bNAB) target specific proteins on the outside of this virus
Broadly neutralizing antibodies (bNAB) target specific proteins on the outside of this virus
After the safety and tolerability of the antibody were determined in this placebo-controlled clinical trial of adults with and without HIV infection and adults receiving antiretroviral therapy (ART) to suppress HIV infection, The authors next evaluated the antibody in HIV adults who were not treated with ART and therefore had a detectable viral load
After the safety and tolerability of the antibody were determined in this placebo-controlled clinical trial of adults with and without HIV infection and adults receiving antiretroviral therapy (ART) to suppress HIV infection, The authors next evaluated the antibody in HIV adults who were not treated with ART and therefore had a detectable viral load
After receiving a single dose of this antibody, the viral load of people with a high baseline viral load decreased and continued to decline for 7 to 10 days before rebounding to the baseline level on the 28th day
After receiving a single dose of this antibody, the viral load of people with a high baseline viral load decreased and continued to decline for 7 to 10 days before rebounding to the baseline level on the 28th day
Dr.
Dr.
Consistent with previous studies on HIV antibody therapy, these authors also observed that 12 of the 13 participants developed at least partial resistance to this antibody --- HIV's ability to rapidly evolve drug therapies and vaccine strategies This is one of the reasons the virus is so difficult to eradicate
Consistent with previous studies on HIV antibody therapy, these authors also observed that 12 of the 13 participants developed at least partial resistance to this antibody --- HIV's ability to rapidly evolve drug therapies and vaccine strategies This is one of the reasons the virus is so difficult to eradicate
Dr.
Dr.
References:
Kathryn E.
Stephenson et al.
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial.
Nature Medicine, 2021, doi:10.
1038/ s41591-021-01509-0.
Kathryn E.
Stephenson et al.
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial.
Nature Medicine, 2021, doi:10.
1038/ s41591-021-01509-0.
Leave a message here
